YAbS







Brenetafusp Clinical Bispecific, Immunoconjugate

Antibody Information

Entry ID 795
INN Brenetafusp
Status Clinical
Drug code(s) IMC-F106C
Brand name None
mAb sequence source mAb - source TBD
General Molecular Category Bispecific, Immunoconjugate
Format, general category Fragment fusion
Format details scFv-TCR
Isotype (Fc) None
Light chain isotype TBD
Linker None
Ave. DAR None
Conjugated/fused moiety T cell receptor
Discovery method/technology None

Therapeutic information

Target(s) PRAME, CD3
Indications of clinical studies PRAME-Positive Cancers
Primary therapeutic area Cancer

Development stage information

Phase lengths*
*The graph represents early-stage clinical development phase lengths. For molecules approved or under evaluation for marketing authorization in the US is provided a complete overview of all clinical development phase lengths. Phase lengths are calculated from the start of the first in human (FIH) study (Start of clinical phase). “Start of Phase 2” bar represents Phase 1 length (Start of clinical phase to start of Phase 2); “Start of Phase 3” bar represents Phase 1+2 length (Start of clinical phase to start of Phase 3); “Date BLA/NDA submitted” bar represents Phase 1+2+3 length (Start of clinical phase to Date BLA/NDA submitted); and “Date of first US approval” bar represents Phase 1 to first US approval length (Start of clinical phase to Date of first US approval).
Most advanced stage of development (global) Phase 3
Status Active
Start of clinical phase (IND filing or first Phase 1) February 25, 2020
Start of Phase 2
Start of Phase 3 December 18, 2023
Date BLA/NDA submitted to FDA
Year of first approval (global) None
Date of first US approval
INN, US product name None
US or EU approved indications None

Company information

Company Immunocore Ltd
Licensee/Partner None
Comments about company or candidate NCT06112314 Phase 3 study in melanoma started in Dec 2023.
NCT04262466 Phase 1/2 study started Feb 25 2020 recruiting as of last update in Dec 2022.
Full address of company 92 Park Drive, Milton Park, Abingdon, Oxon, OX14 4RY, UK
Europe
United Kingdom
https://www.immunocore.com/contact-us

Description/comment

IMC-F106C is an immune-mobilizing T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME PRAME = PReferentially expressed Antigen in Melanoma. Developed using ImmTac technology; molecule combines a T cell receptor-targeting system with an anti-CD3 antibody-based binding site.

Additional information

Anticipated events None
Factor(s) contributing to discontinuation None